Potential Role of MicroRNA-210 as Biomarker in Human Cancers Detection: A Meta-Analysis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lu, Jiongjiong ^a   Xie, Feng ^a   Geng, Li ^a   Shen, Weifeng ^a   Sui, Chengjun ^a   Yang, Jiamei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; META ANALYSIS; PANCREAS CANCER; PUBLISHING; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; AREA UNDER THE CURVE; FACTUAL DATABASE; FEMALE; GENETICS; MALE; METABOLISM; NEOPLASM; RECEIVER OPERATING CHARACTERISTIC;

AREA UNDER CURVE; BIOMARKERS, TUMOR; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MICRORNAS; NEOPLASMS; ROC CURVE;

EID: 84942744159     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/303987     Document Type: Review

References (43)

1. A. Jemal, R. Siegel, E.Ward et al., "Cancer statistics, 2008," CA: A Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71-96, 2008.
2. X. Li, K. Wu, and D. Fan, "CIAPIN1 as a therapeutic target in cancer," Expert Opinion on Therapeutic Targets, vol. 14, no. 6, pp. 603-610, 2010.
3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
4. R. J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara, "Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma," Journal of Clinical Oncology, vol. 17, no. 8, pp. 2530-2540, 1999.
5. H. Iwamoto, Y. Kanda, T. Sejima, M. Osaki, F. Okada, and A. Takenaka, "Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma," International Journal of Oncology, vol. 44, no. 1, pp. 53-58, 2014.
6. J. K. Frost, W. C. Ball Jr., M. L. Levin et al., "Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins Study," American Review of Respiratory Disease, vol. 130, no. 4, pp. 549-554, 1984.
7. F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and Jr. Bunn P. A., "Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology," Clinical Cancer Research, vol. 7, no. 1, pp. 5-22, 2001.
8. J. Wittmann and H.-M. Jäck, "Serum microRNAs as powerful cancer biomarkers," Biochimica et Biophysica Acta - Reviews on Cancer, vol. 1806, no. 2, pp. 200-207, 2010.
9. F. Lumachi, A. A. Brandes, M. Ermani, G. Bruno, and P. Boccagni, "Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors," Anticancer Research, vol. 20, no. 6C, pp. 4751-4755, 2000.
10. J. Schneider, H.-G. Velcovsky, H. Morr, N. Katz, K. Neu, and E. Eigenbrodt, "Comparison of the tumor markers Tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer," Anticancer Research, vol. 20, no. 6 D, pp. 5053-5058, 2000.
11. H. A. Dbouk, A. Tawil, F. Nasr et al., "Significance of CEA and VEGF as diagnostic markers of colorectal cancer in Lebanese patients,"The Open Clinical Cancer Journal, vol. 1, pp. 1-5, 2007.
12. S. M. Hanash, C. S. Baik, and O. Kallioniemi, "Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer," Nature Reviews Clinical Oncology, vol. 8, no. 3, pp. 142-150, 2011.
13. G. Hutvágner and P. D. Zamore, "A microRNA in a multipleturnover RNAi enzyme complex," Science, vol. 297, no. 5589, pp. 2056-2060, 2002.
14. A. Esquela-Kerscher and F. J. Slack, "Oncomirs - microRNAs with a role in cancer," Nature Reviews Cancer, vol. 6, no. 4, pp. 259-269, 2006.
15. B. Zhang, X. Pan, G. P. Cobb, and T.A.Anderson, "microRNAs as oncogenes and tumor suppressors," Developmental Biology, vol. 302, no. 1, pp. 1-12, 2007.
16. J. Wang, J. Chen, P. Chang et al., "MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel bloodbased biomarkers of disease," Cancer Prevention Research, vol. 2, no. 9, pp. 807-813, 2009.
17. L. Xing, N. W. Todd, L. Yu, H. Fang, and F. Jiang, "Early detection of squamous cell lung cancer in sputum by a panel of microRNAmarkers," Modern Pathology, vol. 23, no. 8, pp. 1157-1164, 2010.
18. J. Shen, Z. Liu, N. W. Todd et al., "Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers," BMC Cancer, vol. 11, article 374, 2011.
19. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating microRNAs as stable blood-based markers for cancer detection," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513-10518, 2008.
20. J. A. Weber, D. H. Baxter, S. Zhang et al., "The microRNA spectrum in 12 body fluids," Clinical Chemistry, vol. 56, no. 11, pp. 1733-1741, 2010.
21. X. Chen, Y. Ba, L.Ma et al., "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases," Cell Research, vol. 18, no. 10, pp. 997-1006, 2008.
22. A. Turchinovich, L. Weiz, A. Langheinz, and B. Burwinkel, "Characterization of extracellular circulating microRNA," Nucleic Acids Research, vol. 39, no. 16, pp. 7223-7233, 2011.
23. R. Kulshreshtha, M. Ferracin, S. E.Wojcik et al., "A microRNA signature of hypoxia,"Molecular and Cellular Biology, vol. 27,no. 5, pp. 1859-1867, 2007.
24. A. Osman, "MicroRNAs in health and disease - basic science and clinical applications," Clinical Laboratory, vol. 58, no. 5-6, pp. 393-402, 2012.
25. M. E. Crosby, C. M. Devlin, P. M. Glazer, G. A. Calin, and M. Ivan, "Emerging roles ofmicroRNAs in themolecular responses to hypoxia," Current Pharmaceutical Design, vol. 15, no. 33, pp. 3861-3866, 2009.
26. J. Shen, N. W. Todd, H. Zhang et al., "Plasma microRNAs as potential biomarkers for non-small-cell lung cancer," Laboratory Investigation, vol. 91, no. 4, pp. 579-587, 2011.
27. H. Xie, Z. Chu, and H. Wang, "Serum microRNA expression profile as a biomarker in diagnosis and prognosis of acute myeloid leukemia," Journal of Clinical Pediatric Dentistry, vol. 30, no. 5, pp. 421-424, 2012.
28. N. Anjuman, N. Li, M. Guarnera, S. A. Stass, and F. Jiang, "Evaluation of lung flute in sputum samples for molecular analysis of lung cancer," Clinical and TranslationalMedicine, vol. 2, article 15, 2013.
29. D. Madhavan, K. Cuk, B. Burwinkel, and R. Yang, "Cancer diagnosis and prognosis decoded by blood-based circulating micro RNA signatures," Frontiers in Genetics, vol. 4, article 116, 2013.
30. L. Hong, J. Yang, Y. Han, Q. Lu, J. Cao, and L. Syed, "High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis," Gene, vol. 507, no. 2, pp. 135-138, 2012.
31. Y. Li, X. Ma, J. Zhao, B. Zhang, Z. Jing, and L. Liu, "microRNA-210 as a prognostic factor in patients with breast cancer: metaanalysis," Cancer Biomarkers, vol. 13, no. 6, pp. 471-481, 2013.
32. D. Madhavan, M. Zucknick, M. Wallwiener et al., "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers inmetastatic breast cancer," Clinical Cancer Research, vol. 18, no. 21, pp. 5972-5982, 2012.
33. Y. Ren, J. Gao, J.-Q. Liu et al., "Differential signature of fecal microRNAs in patients with pancreatic cancer,"Molecular Medicine Reports, vol. 6, no. 1, pp. 201-209, 2012.
34. A. Zhao, G. Li, M. Péoc'h, C. Genin, and M. Gigante, "Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma," Experimental and Molecular Pathology, vol. 94, no. 1, pp. 115-120, 2013.
35. N. Li, J. Ma,M.A.Guarnera, H. Fang, L.Cai, and F. Jiang, "Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer," Journal of Cancer Research and Clinical Oncology, vol. 140, no. 1, pp. 145-150, 2014.
36. J. Shen, J. Liao, M. A. Guarnera et al., "Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis," Journal ofThoracic Oncology, vol. 9, no. 1, pp. 33-40, 2014.
37. E. C. Vamvakas, "Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods," Archives of Pathology&Laboratory Medicine, vol. 122, no. 8, pp. 675-686, 1998.
38. A. J. Mitchell, A. Vaze, and S. Rao, "Clinical diagnosis of depression in primary care: a meta-analysis," The Lancet, vol. 374, no. 9690, pp. 609-619, 2009.
39. J. Dinnes, J. Deeks, J. Kirby, and P. Roderick, "Amethodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy," Health Technology Assessment, vol. 9, no. 12, pp. 1-113, 2005.
40. J. J. Deeks, P.Macaskill, and L. Irwig, "The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed," Journal of Clinical Epidemiology, vol. 58, no. 9, pp. 882-893, 2005.
41. C. Devlin, S. Greco, F. Martelli, and M. Ivan, "MiR-210: more than a silent player in hypoxia," IUBMB Life, vol. 63, no. 2, pp. 94-100, 2011.
42. R. H.Wenger andM. Gassmann, "Oxygen(es) and the hypoxiainducible factor-1," Biological Chemistry, vol. 378, no. 7, pp. 609-616, 1997.
43. C. S. Neal, M. Z. Michael, L. H. Rawlings, M. B. van der Hoek, and J. M. Gleadle, "The VHL-dependent regulation of microRNAs in renal cancer," BMC Medicine, vol. 8, article 64, 2010.